Capital Performance Advisors’s Gilead Sciences GILD Stock Holding History

Capital Performance Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$925K	Sell	7,324 -1,291	-15%	-$170K	0.06%	119
2026 Q1	$1.2M	Sell	8,615 -784	-8%	-$110K	0.08%	109
2025 Q4	$1.15M	Buy	9,399 +4,077	+77%	+$495K	0.08%	105
2025 Q3	$591K	Buy	5,322 +179	+3%	+$20.3K	0.1%	111
2025 Q2	$570K	Sell	5,143 -44	-0.8%	-$4.68K	0.11%	98
2025 Q1	$581K	Buy	+5,187	New	+$535K	0.13%	87
2024 Q4	–	Sell	-1,723	Closed	-$144K	–	1140
2024 Q3	$144K	Buy	+1,723	New	+$131K	0.04%	143

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Performance Advisors's GILD Position: Q2 2026 in Review

Capital Performance Advisors reduced its Gilead Sciences (GILD) stake by 15% in Q2 2026, selling an estimated $170K and leaving 7,324 shares worth $925K. The position accounts for 0.06% of the portfolio, ranked #119.

Capital Performance Advisors first reported a position in GILD in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.2M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Capital Performance Advisors held 7,324 shares of Gilead Sciences worth $925K as of Q2 2026.
Capital Performance Advisors sold 1,291 Gilead Sciences shares in Q2 2026, an estimated $170K.
Gilead Sciences made up 0.06% of Capital Performance Advisors's portfolio in Q2 2026, its #119 holding.
Capital Performance Advisors first reported a position in Gilead Sciences in Q3 2024 and has held it in 7 quarters since.
Capital Performance Advisors's Gilead Sciences position peaked at $1.2M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.